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Abstract Biologic therapies have revolutionized treatment
of a number of diseases. Patents and exclusivity for a
number of biologics are expiring. This has created the
opportunity for the development and approval of biosimi-
lars. Biosimilars are biologic products developed using a
step-wise approach to result in a biologic that demonstrates
no clinically meaningful differences in terms of quality
attributes, efficacy, safety, and immunogenicity compared
with an existing licensed, originator biologic. As more
biosimilars receive regulatory approval and reach the
market, it is increasingly important for healthcare providers
to understand the terminology about biosimilars. To help
support healthcare providers, the aim of this manuscript is
to (i) support understanding of the language of biosimilars,
(ii) review the regulatory and manufacturing processes
employed in developing a biosimilar, and (iii) provide
information for clinical decisions about the use of
biosimilars. Because biologics are large, structurally com-
plex proteins, biosimilars cannot be considered generic
equivalents to the originator. Biosimilars are developed and
evaluated using rigorous processes involving detailed
analytical and functional studies, nonclinical assessments,
and clinical trials. Clinical studies evaluating the potential
biosimilar are designed differently than those for approval
of a novel biologic since the aim is merely to confirm
similar efficacy and safety and not to demonstrate clinical
benefit per se. Extrapolation of data may be used to grant
approval of biosimilars in indications not directly evaluated
in clinical studies using the biosimilar.
Key Points
The potential exists for more biosimilars to become
available over the next few years; therefore, it is
important for healthcare providers to understand the
terminology used to describe development and
approval of biosimilars.
Biosimilars undergo a rigorous evaluation using the
criteria defined in the EMA, FDA, or WHO
biosimilar guidelines before regulatory approval.
Biosimilar approval is based on the totality of data
demonstrating similarity between the biosimilar and
the originator, including in terms of quality
characteristics, biological activity, safety, and
efficacy.
1 Introduction
Biologic therapies have revolutionized the treatment of a
variety of conditions, including cancers and autoimmune
diseases. Patents and other periods of exclusivity for a
number of biologics are nearing expiration or have already
expired, leading to the development and approval of
products (called ‘biosimilars’) that are similar to licensed
biologic products [1]. The European Medicines Agency
(EMA) has approved over 20 biosimilars since the
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development of specific guidelines and recommendations
for evaluation of these agents [2, 3]. In 2015, the United
States Food and Drug Administration (FDA) approved its
first biosimilar (a biosimilar to filgrastim) under the Bio-
logics Price Competition and Innovation Act of 2009 [4].
As a number of the highly utilized biologics will lose
patent exclusivity by 2020, the potential exists for even
more biosimilars to become available over the next few
years [5]. As more biosimilars are approved and prescribed,
it is increasingly important for healthcare providers to
understand the terminology about biosimilars. To address
this need, the aim of this manuscript is to (i) support
understanding of the language of biosimilars, (ii) review
the regulatory and manufacturing processes employed in
developing a quality biosimilar, and (iii) provide infor-
mation for clinical decisions about the use of biosimilars.
2 Defining a Biosimilar
Biosimilars are different from both originator biologic
products and generic small molecule drugs in terms of their
development and regulatory approval [1, 2]. As a result,
there is a unique lexicon of terms used to describe the
development, evaluation, and/or approval of biosimilars
(Table 1). A biosimilar is a biological product that is
approved based on the totality of evidence demonstrating
that it is highly similar to an approved biological product
(originator) in terms of structure, function, quality, and
clinical efficacy and safety [1, 2, 6]. Biosimilars are
developed such that there are ‘‘no clinically meaningful
differences between the biological product and the refer-
ence [originator] product in terms of safety, purity, and
potency’’ [6]. The EMA definition further clarifies that ‘‘a
biosimilar demonstrates similarity to the [originator] in
terms of quality characteristics, biological activity, safety,
and efficacy based on a comprehensive comparability
exercise’’ [2]. Unlike small molecule (chemical) drugs that
can be fully defined structurally so generic versions can be
produced, biologics are large, structurally complex prod-
ucts isolated from natural sources (including proteins,
nucleic acids, or combinations of these, or living entities
such as cells and tissues) and subject to post-translational
structural modifications that lead to an intrinsic hetero-
geneity [1, 2, 7]. Thus, biosimilars cannot be considered
generic equivalents to the originator and require additional
characterization to confirm comparable clinical efficacy
and safety [1, 2, 7].
The development and approval of a biosimilar is dif-
ferent from the process used for a new molecular entity.
For one thing, the analyses and clinical trials for potential
biosimilars compare the physicochemical and biological
properties and short-term efficacy and safety to the origi-
nator; they do not re-establish the mechanism of action or
proof of concept [1, 2]. In addition, because the manu-
facturing process for the originator is proprietary, the
biosimilar developer must analyze the originator exten-
sively and use reverse engineering to develop the
Table 1 Lexicon of terms and definitions used to describe biosimilars
Term Definition
Biologic An approved product composed of proteins, nucleic acids, or combinations of these, or living entities such as cells and
tissues, which is isolated from natural sources (including humans, animals, and microorganisms) and produced by
biotechnology methods and other cutting-edge technologies [34]
Biosimilar A biological product developed such that there are ‘‘no clinically meaningful differences between the biological product
and the reference [originator] product in terms of safety, purity, and potency’’ and ‘‘demonstrates similarity to the
[originator] in terms of quality characteristics, biological activity, safety, and efficacy based on a comprehensive
comparability exercise’’ [1, 2, 6]
Generic drug Small (single molecule) or low molecular weight chemically synthesized compounds consisting of a simple, well
defined structure that is independent of the manufacturing process and easy to characterize completely [35]
Extrapolation A core concept for approval of biosimilars, extrapolation allows for the approval of a biosimilar for use in an indication
held by the originator not directly studied in clinical trials of the biosimilar. It is based on sufficient scientific
justification and the totality of the evidence [1, 2, 29]
Interchangeable
biosimilar
The product is approved as a biosimilar; the biosimilar can be expected to produce the same clinical effects as the
originator in any given patient, and the risk in terms of safety or diminished efficacy of alternating or switching
between use of the product and its originator is not greater than the risk of using the originator without such alternation
or switch [23]
NOTE: This designation is only granted by the FDA; the EMA and WHO do not provide any regulatory statement on
whether or not a biosimilar is considered interchangeable [20, 21, 29]
Intended copy Copies of an originator biologic that have not been evaluated using the stringent, specifically defined criteria of the
EMA, FDA, or WHO guidelines for biosimilars [26]
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biosimilar [8]. As described earlier, biologics are relatively
large, complex proteins that are difficult to characterize, so
regulatory processes for biosimilar approval are also not
the same as those used for small-molecule generics (which
usually just requires demonstration of bioequivalence of
the generic medicine to the licensed originator small-
molecule drug) [1].
3 Development and Regulatory Approval
of Biosimilars
Because biosimilars have many specific and unique con-
siderations related to regulatory approval, specific guide-
lines have been developed by the EMA, the FDA, and the
World Health Organization (WHO) [1, 2, 6]. There are
minor differences among guidelines, but all suggest fol-
lowing a step-wise approach to demonstrate biosimilarity
with the originator [1, 2, 6].
Biosimilars are developed and evaluated in rigorous
processes involving extensive analytical and functional
studies; limited nonclinical assessments of pharmacoki-
netics (PK) and toxicity; and limited clinical evaluation of
PK, efficacy, and safety [1, 2, 6]. Data supporting the
demonstration of biosimilarity to the originator are based
on a foundation of extensive analytical studies to compare
the structural, physicochemical, and functional character-
istics of the potential biosimilar and originator
[1, 2, 6, 8, 9]. Minor differences in structure (such as
glycosylation variants) may occur, yet the product may be
considered a biosimilar as long as the structural differences
are expected not to have a clinically meaningful impact on
efficacy and/or safety [6]. After confirming a high degree
of physicochemical and functional similarity, nonclinical
studies may be conducted to demonstrate that the potential
biosimilar has similar PK and toxicity to the originator
[1, 2, 6, 8]. It should be noted that a paradigm shift has
occurred in Europe in which the decision to conduct in vivo
nonclinical studies is made as part of the step-wise
approach and these studies are not performed by default
[10]. The US guidelines also suggest a step-wise approach,
although they do not specifically state that approval can be
granted without nonclinical in vivo studies and have
required at least one nonclinical in vivo study to date [11].
Finally, while the size and scope of the clinical program
depends on data generated in the comparative analytical
and nonclinical studies, the guidelines recommend
including at least one human PK study and generally a
minimum of one efficacy and safety study evaluating
biosimilarity to the originator [1, 2, 6, 8].
Compared with the approval pathway for a novel bio-
logic, the biosimilar approval pathway places more
emphasis on data from comparative analytical studies and
less on those from clinical trials. For example, biosimilars
do not require studies to evaluate mechanism of action,
determine optimal dosing, or demonstrate patient benefit
because these were established by the originator [1, 2].
Instead, clinical studies evaluating a potential biosimilar
serve to confirm similar efficacy and safety (including
potency, PK, pharmacodynamics [PD], and immuno-
genicity) with respect to the originator [1, 2, 6].
4 Study Design
Clinical studies of potential biosimilars are conducted
using a study population sensitive to detecting potential
differences in efficacy, safety, or immunogenicity between
the biosimilar and originator [1, 2, 6]. Thus, this population
may include a different patient population than that
employed in pivotal clinical trials of the originator [1, 2, 6].
In addition, the primary endpoints measured may or may
not be the same as those used in those pivotal clinical trials
[1, 2, 6]. Endpoints such as PD measures (a biomarker
linked to efficacy so that it is considered an accepted sur-
rogate; e.g., absolute neutrophil count and CD34? cell
count are PD measures for granulocyte colony stimulating
factor) are considered sensitive clinical endpoints for
evaluating biosimilarity and may be selected as the primary
endpoints of a biosimilar clinical study to facilitate more
precise efficacy comparisons to the originator [1, 2, 6].
Regulatory guidelines also recommend including some
endpoints commonly used in the pivotal trials of the orig-
inator as secondary endpoints to enable comparisons across
products [1, 2, 6].
Originator biologics were approved based upon the
demonstration of clinically meaningful efficacy and safety
versus a placebo, current therapeutic options, or current
standard of care in clinical trials [12]. For regulatory
approval, the biosimilar is expected to exhibit similar
efficacy and safety profiles compared with the originator in
clinical studies [1, 2, 6]. Regulatory guidelines recommend
an equivalence trial since this should allow testing of the
hypothesis that the treatments (the biosimilar and origina-
tor) result in no clinically meaningful differences
[1, 6, 12, 13]. The exact nature of statistical analyses for
biosimilars depends on the trial design employed [1, 12].
5 Extrapolation
One of the core concepts in the development and approval
of biosimilars is the concept of extrapolation, which allows
for the approval of a biosimilar for use in an indication held
by the originator that was not directly studied in clinical
trials using the biosimilar [1, 2, 6]. One misconception
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about extrapolation is that the decision to allow extrapo-
lation of indications is based only on clinical data when, in
fact, the decision is based on the totality of the evidence,
including the structural, physicochemical, functional, and
nonclinical data in addition to clinical evaluations, all of
which must support similarity of the biosimilar to the
originator [8]. Because of the possibility of extrapolation,
the biosimilar may not need to be evaluated in clinical
studies for each indication [1, 6]. This means that the entire
clinical program of the originator does not have to be
duplicated for the potential biosimilar. Thus, the number of
clinical studies required for approval of the biosimilar is
reduced compared with the number of studies conducted
for approval of the originator [8].
To support extrapolation to other indications, sufficient
data are necessary to provide scientific justification
[1, 6, 14]. To be considered supportive of extrapolation,
data should be based on studies using a sensitive clinical
model to detect potential differences between the originator
and the potential biosimilar [1, 6, 14]. The indications also
should have the same molecular mechanism of action,
involve the same receptors, have a similar binding dose-
response and pattern of molecular signaling upon target
binding, and have similar location and expression of the
target [1, 6, 14]. The totality of the data should also include
well characterized PK and biodistribution information as
well as sufficient characterization of safety and immuno-
genicity to indicate that the potential biosimilar does not
have unique or additional safety issues versus the origi-
nator [1, 6, 14].
Because the decision to allow extrapolation of data to
indications is made on an agency-by-agency basis, not all
regulatory agencies may come to the same conclusion
about a given product [8]. This is demonstrated by the case
of the recent approvals of biosimilars to infliximab, for
which some regulatory agencies granted approval for the
full range of indications of the originator whereas other
regulatory agencies did not [8]. Health Canada initially
determined that the data provided for the regulatory
approval of infliximab biosimilars manufactured by Cell-
trion Healthcare Co. Ltd (Yeonsu-gu, Incheon, Republic of
Korea) and distributed by Hospira Healthcare Corporation
(Kirkland, Quebec, Canada) were indicative of structural
and functional differences that were potentially clinically
relevant and therefore excluded extrapolation to Crohn’s
disease and ulcerative colitis [8, 15, 16]. Specifically, dif-
ferences in antibody-dependent cell-mediated cytotoxicity
(ADCC) assays suggested the biosimilars may differ from
the originator in the ability to induce ADCC [15, 16]. Since
ADCC may be involved in inflammatory bowel diseases
such as Crohn’s disease and ulcerative colitis, extrapolation
to these therapeutic indications was initially not recom-
mended for the two biosimilars of infliximab [15, 16].
More recently, Health Canada approved both biosimilars
for Crohn’s disease, fistulizing Crohn’s disease, and
ulcerative colitis based on previously submitted clinical
data that formed the basis for the initial approval (for
rheumatoid arthritis, ankylosing spondylitis, psoriatic
arthritis, and plaque psoriasis), newly submitted physico-
chemical and biological data (including non-comparative,
observational clinical data in patients with inflammatory
bowel diseases), and scientific rationales with respect to the
molecular mechanism of action and approved indications
for the originator [17, 18].
6 Interchangeability and Substitution
The review process and designation of interchangeability
requires additional standards [19]. The designation of
interchangeability may be granted after a biosimilar has
been approved; interchangeability is not automatically
granted upon regulatory approval of a biosimilar [19, 20].
The EMA does not regulate whether a biosimilar is con-
sidered interchangeable with the originator because inter-
changeability is regulated on the national level [20, 21].
Similarly, the WHO does not elaborate on interchange-
ability and substitution of biosimilars in their guidance
documents [1]. Thus, the FDA is the only regulatory
agency with a statutory definition of interchangeability and
the authority to approve biosimilars that are interchange-
able with the originator [20, 22]. Draft guidance on inter-
changeability was issued by the FDA in January 2017 [19].
These guidelines state that for a biosimilar to be considered
interchangeable, it ‘‘is biosimilar to the reference product’’
and ‘‘can be expected to produce the same clinical result as
the reference product in any given patient’’ and that ‘‘for a
biological product that is administered more than once to
an individual, the risk in terms of safety or diminished
efficacy of alternating or switching between use of the
biological product and the reference product is not greater
than the risk of using the reference product without such
alternation or switch’’ [19]. The designation of a biosimilar
as interchangeable means ‘‘the biological product may be
substituted for the reference product without the interven-
tion of the healthcare provider who prescribed the refer-
ence product’’ [19].
One important consideration in the use of biosimilars is
that multiple (independently developed) biosimilars could
receive the designation of interchangeable with the origi-
nator. Since interchangeability is determined for a product
versus the originator, it is unlikely that biosimilars will be
compared to each other in formal head-to-head compar-
isons. There are some published comparisons of multiple
biosimilars based on indirect evaluation of their properties.
For example, a comparison of the properties of two epoetin
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biosimilars (HX575 [epoetin alfa] and SB309 [epoetin
zeta]) indicated there were some differences in PK and
dosing even though both were independently approved as
biosimilars to the same originator epoetin by the EMA
[24]. Specifically, for HX575, there were some PK differ-
ences versus the originator product epoetin alfa (Janssen-
Cilag, New York, NY, USA)—such as a lower area under
the curve (AUC)0–12h for HX575 versus epoetin alfa of
18% after a single dose; a steady state AUC0–36h that was
approximately 10% lower; and a 10% reduction in expo-
sure—although HX575 and the originator epoetin alfa were
considered pharmacokinetically equivalent following
multiple IV administrations [24]. Similarly, a crossover
study comparing SB309 to epoetin alfa required modifi-
cations in dosing (switching from epoetin alfa to SB309
increased the dose required by approximately 10–15% and
switching from SB309 to epoetin alfa reduced the dose
required by around 10%), and modest changes in hemo-
globin levels were observed [24]. Analysis of the total
protein content showed that the amount of SB309 was
lower than the amount of epoetin alfa so a correction based
on the protein content was performed and the 90% CIs for
the corrected values were well within the post-hoc defined
equivalence [25]. Thus, SB309 met the bioequivalence
endpoints required for approval in the EMA [24]. It is
important to realize that this comparison was based on the
published results supporting approval for each biosimilar
and not on a clinical trial directly comparing the two
biosimilars. This example demonstrates the need for clear
and unambiguous guidance around interchangeability when
multiple biosimilars of the same originator are available.
Once a biosimilar is designated as an ‘interchangeable
biological product’ by the FDA, further regulation may be
established at the state government level as to whether an
interchangeable product may be substituted by the phar-
macist [20]. When allowed, substitution may be done with
or without the pharmacist notifying the prescriber (the
latter is known as ‘automatic substitution’) [20].
7 Differences Between Biosimilars and Intended
Copies
In some countries, there are commercially available agents
that are copies of the originator but which have not been
evaluated using the stringent, specifically defined criteria of
the WHO guidelines for biosimilars [26]. These agents,
called intended copies or biomimics, may have been
approved prior to the development of approval guidelines
or under guidelines considered less strict than those from
the EMA, FDA, or WHO [26–28]. Intended copies have
not undergone evaluation according to the stringent regu-
latory pathways used for biosimilars [26–28]. In addition,
intended copies may have differences in formulation or
dosages that could result in a clinically significant impact
on efficacy and/or safety [26]. Thus, intended copies can-
not be considered biosimilars of the originator.
8 Are Originators Biosimilars of Themselves?
For manufacturers of biologics, planned changes in man-
ufacturing may occur over the life of the product. This is
particularly true for changes in scale, manufacturing
equipment, and improving efficiency, although changes to
cell line also may (rarely) occur [9]. To address this, the
FDA has generated guidance for industry for assessing
biologics undergoing changes in manufacturing (by the
same manufacturer; called the ‘comparability exercise’)
[9, 29]. These guidelines indicate that quality data should
be generated on the product prior to and after the manu-
facturing change and then analyzed using a comparison
integrating all data [29]. The goal of the comparability
exercise is to ensure the resulting product has consistent
quality, safety, and efficacy using relevant data and that
attributes of the biologic pre- and post-change are highly
similar [29]. However, demonstration of comparability
does not necessarily mean that pre- and post-change
products are identical [29]. Ongoing, routine batch analy-
ses, in-process control, process validation and/or evaluation
data, characterization, and stability analyses are performed
and compared to historic data to ensure batch variability
and process changes have no adverse impact upon safety or
efficacy [29]. It is important to note that for the assess-
ments of a product undergoing a manufacturing change,
manufacturers of an approved product know the product
development history, cell line, entire production and
purification process, and critical proprietary information
[9]. As a result, changes in the manufacturing process can
be conducted using extremely well controlled measures
and internally available intermediates [9, 29].
In contrast, while the statistical approach to assessing a
product pre-and post-change is similar to the analysis used
to assess a potential biosimilar to an originator, the
development process itself is very different because
developers of potential biosimilars face a large knowledge
gap in the manufacturing processes used for the originator
[9]. As a result, developers of biosimilars must use reverse
engineering to develop the product. This starts with the
selection of a new cell line since they will not have access
to the same cell line used by the manufacturer of the
originator [9]. As a result, they will also need to establish a
new production and purification process to reflect inherent
differences in cell lines [9]. Although the concepts of
comparability (evaluation of an original biologic after a
manufacturing change) and biosimilarity (evaluation of a
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new biosimilar against the originator product) are related
scientific and regulatory concepts (these terms are even
used interchangeably in the EMA biosimilar guidelines),
these are two very distinct processes from a developmental
point of view [9]. As a result, originators undergoing
manufacturing changes should not be considered biosimi-
lars of themselves [9].
9 Future Perspectives and Challenges
Although guidance for the approval of biosimilars has been
available for several years, some concepts still need to be
addressed to ensure that efficient pharmacovigilance is
performed to support the safe and effective treatment of
patients. For example, regulatory approval usually requires
the provision of appropriate ongoing, post-approval safety
monitoring programs [1, 6]. It is important to note that
currently there are no standard requirements for post-ap-
proval safety monitoring programs because they may
depend on experience from the originator. Therefore, these
programs are developed through discussions between the
manufacturer and regulatory authorities to determine which
appropriate study design or surveillance (e.g., patient reg-
istries) should be in place to evaluate any risks to safety
[1, 6]. In addition, it is critical these programs have ade-
quate mechanisms in place to differentiate between adverse
events associated with a biosimilar and those associated
with the originator [6]. Naming conventions for biosimilars
currently are not consistent, with the WHO proposing a
four-letter code (‘biological qualifier’) to the international
non-proprietary name (INN) and the FDA using a four-
letter suffix, whereas member states of the European
Commission’s Pharmaceutical Committee indicate that
biosimilars should use the same INN as the originator
[30–32]. Identification of biosimilars will likely remain a
challenge until harmonization of naming conventions
occurs [33].
10 Conclusion
As biologic products lose patent exclusivity and more
biosimilars receive regulatory approval, the terminology
and definitions applied to biosimilars need to be clarified
and used consistently. This is especially critical when
multiple biosimilars of the same product are available. It is
important to be clear about whether a specific product has
been evaluated through a rigorous evaluation procedure
based on the criteria defined in the EMA, FDA, or WHO
biosimilar guidelines. It is also important for prescribers to
understand what happens when a particular biosimilar
receives a designation of ‘interchangeable’ with the
originator and when substitution may occur, as these des-
ignations/policies may impact patient outcomes.
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